Background
The aim of this study is to detect whether there is a significant difference between patients receiving 100 mg enteric coated salicylate before coronary artery surgery with patients not receiving in terms of postoperative mortality rates.
Methods
Sixty one patients that underwent coronary bypass surgery between January 2011 and December 2011 at our clinic were investigated retrospectively. Sixty one (80.3%) of them were operated on under cardiopulmonary bypass and 12 (19.7%) were operated on beating heart. Thirty (49.2%) of them were receivers of 100 mg enteric coated salicylate and 31 (50.8%) were non-receivers, divided into 2 groups. The mean age of salicylate receivers was 61.33 years whereas it was 57.71 years in the non-receivers.
Results
The mortality rate was 4.5% for cases receiving salicylate that underwent coronary surgery using cardiopulmonary bypass (CPB), and 3.7% for cases not receiving salicylate. No significant difference was seen (p>0.05). No mortality was seen among patients that underwent coronary surgery on beating heart.
Conclusions
In this study, we investigated the patient groups that underwent surgery in either method. Salicylate use did not cause any increase in mortality rate with no significant difference.
